Biopharmaceutical company Foresee Pharmaceuticals (TPEx:6576) announced on Sunday that it has successfully completed its Phase 1 single and multiple ascending dose clinical study in Australia for linvemastat (FP-020), a selective oral MMP-12 inhibitor.
The trial evaluated safety, tolerability, and pharmacokinetics in healthy subjects, with 40 participants in the single dose phase and 24 in the multiple dose phase.
Linvemastat is designed to treat inflammatory and fibrotic diseases, offering greater potency and selectivity than its predecessor, aderamastat (FP-025). Preclinical studies show favorable efficacy in respiratory and inflammatory bowel diseases. MMP-12, a key immune-fibrotic modulator, is linked to disease severity in asthma and COPD. Foresee plans to advance linvemastat for respiratory and fibrotic conditions.
AstraZeneca's Tagrisso Recommended for EU approval for unresectable EGFR-mutated lung cancer
IDEAYA announces IDE034 as development candidate; Secures global license from Biocytogen
ANGLE plc highlights dual CTC and ctDNA analysis in NSCLC research
Mabwell announces promising pre-clinical Data of 7MW4811 at the 15th World ADC Conference
Dizal submits NDA to US FDA for sunvozertinib in treating NSCLC with EGFR exon 20 mutations
Harbour BioMed submits IND application for HBM9378/SKB378 in COPD treatment
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant